Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 7Uterine Cervical Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Blast Crisis 4Vaginal Neoplasms 3Pancreatic Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Leukemia, Myeloid, Acute 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Lymphocytic, Chronic, B-Cell 3Congenital Abnormalities 3Carcinoma, Non-Small-Cell Lung 3Neuroendocrine Tumors 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Myelodysplastic Syndromes 2Lymphoma, Follicular 2Lung Neoplasms 2Leukemia 2Glioblastoma 2Carcinoma, Ovarian Epithelial 2Anemia, Refractory, with Excess of Blasts 2Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Thrombocythemia, Essential 1Sezary Syndrome 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

lutetium Lu 177 dotatate 40Everolimus 35Magnetic Resonance Spectroscopy 15lanreotide 14gallium Ga 68 dotatate 13Temozolomide 13Octreotide 12Nivolumab 12pembrolizumab 11Capecitabine 11surufatinib 10177Lu-octreotide, DOTA(0)-Tyr(3)- 10cabozantinib 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9Sunitinib 8Specimen Handling 7Carboplatin 7telotristat ethyl 6pasireotide 6amino-acid, glucose, and electrolyte solution 6Somatostatin 6Lutetium-177 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5Ipilimumab 5Ga(III)-DOTATOC 5Fluorodeoxyglucose F18 5Etoposide 5Cisplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × 3-aminopyridine-2-carboxaldehyde thiosemicarbazone × Clear all
NCT04234568 2026-06-01

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
31 enrolled 16 charts
EndocrineNET

Neuroendocrine Tumors

NCT05724108 2026-05-13

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
94 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡